Your session is about to expire
← Back to Search
Behavioural Intervention
Remote Monitoring for Breast and Prostate Cancer (PROMOTE Trial)
N/A
Recruiting
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of radiation (average 5 weeks), and 12 weeks after completion of radiation
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to improve the treatment process for breast and prostate cancer patients undergoing radiation therapy (RT). Patients often experience side effects from RT, and by allowing them to self-report these side effects using mobile
Who is the study for?
This trial is for outpatients at Princess Margaret Cancer Centre about to undergo radical or adjuvant radiation therapy for breast or prostate cancer. Participants must be able to use a mobile app in English or French to self-report their health outcomes.
What is being tested?
The study tests if using mobile apps for patients to report side effects (mPROs) and remote monitoring by healthcare providers can improve the timing and quality of patient care during and after radiation therapy.
What are the potential side effects?
While this trial focuses on monitoring rather than medication, potential side effects being reported could include skin reactions, fatigue, digestive issues, urinary problems related to radiation therapy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at the end of radiation (average 5 weeks), and 12 weeks after completion of radiation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of radiation (average 5 weeks), and 12 weeks after completion of radiation
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Remote monitoring efficiency
Secondary study objectives
Influencing factors (disease)
Influencing factors (patient)
Influencing factors (toxicity)
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Remote monitoring PROsExperimental Treatment1 Intervention
All participants allocated to the interventional arm will receive the RT technique, dose and fractionation according to institutional standards. Once per week, participants will use a mobile phone 'app' to enter mPROs, and indicate a need for review for any other reason. The treatment Radiation Therapists will triage the participant to either attend or skip that week's on-treatment review based on this information and established criteria. After RT completion, Advanced Practice Radiation Therapists (apRTs) will triage the participant to receive a virtual follow-up visit when necessary. Participants will be seen once by a Radiation Oncologist 4 to 12 weeks after last radiation treatment. The participants will also complete the following questionnaires: 1) Baseline (patient factors); 2) 'During treatment' (review quality); 3) 'Post acute phase' (satisfaction with care). Circle-of-care HCP will comment on the impact of the PROMOTE process on the quality of care for that participant.
Group II: Standard of CareActive Control1 Intervention
All participants allocated to the standard of care arm will receive all RT treatment activities according to institutional standards. Participants will attend the weekly in-person review session with a Radiation Oncologist during treatment and will be seen once between 4 and 12 weeks after last RT treatment. Documentation of radiation-related toxicity will be performed by the radiation HCPs according to standard of care. Participants will be asked to complete the following study questionnaires: 1) Baseline evaluation (patient factors); 2) 'During treatment' evaluation (need/usefulness of review); 3) 'Post acute phase' evaluation (satisfaction with care).
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,531 Previous Clinical Trials
504,198 Total Patients Enrolled
65 Trials studying Prostate Cancer
15,468 Patients Enrolled for Prostate Cancer